Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab

被引：14
|
作者：
Tejpar, S.
Bokemeyer, C.
Celik, I.
Schlichting, M.
Sartorius, U.
Van Cutsem, E.
机构：
[1] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium
[2] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[3] Merck KGaA, Darmstadt, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.3511
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3511
引用
收藏
页数：1
相关论文
共 50 条
  • [31] ACTIVATING KRAS MUTATIONS AS AN INDEPENDENT PREDICTOR IN METASTATIC COLORECTAL CANCER PATIENTS TREATED WITH CETUXIMAB
    Lin, O. S. R.
    ANNALS OF ONCOLOGY, 2010, 21 : I36 - I36
  • [32] Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis
    Modest, Dominik Paul
    Reinacher-Schick, Anke
    Stintzing, Sebastian
    Giessen, Clemens
    Tannapfel, Andrea
    Laubender, Ruediger Paul
    Brodowicz, Thomas
    Knittelfelder, Regina
    Vrbanec, Damir
    Schmiegel, Wolff
    Heinemann, Volker
    Zielinski, Christoph C.
    ANTI-CANCER DRUGS, 2012, 23 (06) : 666 - 673
  • [33] Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer
    Bai, Long
    Wang, Feng
    Li, Zhe-zhen
    Ren, Chao
    Zhang, Dong-sheng
    Zhao, Qi
    Lu, Yun-xin
    Wang, De-shen
    Ju, Huai-qiang
    Qiu, Miao-zhen
    Wang, Zhi-qiang
    Wang, Feng-hua
    Xu, Rui-hua
    MEDICINE, 2016, 95 (51) : e4531
  • [34] Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model
    Alamo, Patricia
    Gallardo, Alberto
    Di Nicolantonio, Federica
    Pavon, Miguel Angel
    Casanova, Isolda
    Trias, Manuel
    Mangues, Maria Antonia
    Lopez-Pousa, Antonio
    Villaverde, Antonio
    Vazquez, Esther
    Bardelli, Alberto
    Cespedes, Maria Virtudes
    Mangues, Ramon
    FASEB JOURNAL, 2015, 29 (02): : 464 - 476
  • [35] QUALITY OF LIFE ANALYSIS IN PATIENTS WITH KRAS WILD-TYPE METASTATIC COLORECTAL CANCER TREATED WITH FIRST-LINE FOLFIRI PLUS CETUXIMAB
    Lang, I.
    Koehne, C.
    Folprecht, G.
    Rougier, P.
    Curran, D.
    Hitre, E.
    Sartorius, U.
    Griebsch, I.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2012, 23 : 191 - 192
  • [36] The efficacy of antiepidermal growth factor receptor monoclonal antibodies for patients with KRAS G13D mutations and chemorefractory metastatic colorectal cancer.
    Akiyoshi, Kohei
    Yamada, Yasuhide
    Takahashi, Naoki
    Honma, Yoshitaka
    Iwasa, Satoru
    Kato, Ken
    Hamaguchi, Tetsuya
    Shimada, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [37] Observational study of first-line chemotherapy including cetuximab in patients with metastatic colorectal cancer: CORAL trial
    Muro, Kei
    Itabashi, Michio
    Hashida, Hiroki
    Masuishi, Toshiki
    Bando, Hiroyuki
    Denda, Tadamichi
    Yamanaka, Takeharu
    Ohashi, Yasuo
    Sugihara, Kenichi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (04) : 339 - 346
  • [38] The role of KRAS-p.G13D-mutation in metastatic colorectal cancer for patients receiving first-line therapy with FOLFIRI and bevacizumab
    Modest, D. P.
    Stintzing, S.
    Jung, A.
    Neumann, J.
    von Weikersthal, Fischer L.
    Vehling-Kaiser, U.
    Giessen, C.
    Schulz, C.
    Kirchner, T.
    Heinemann, V.
    Modest, D.
    ONKOLOGIE, 2011, 34 : 189 - 189
  • [39] Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study
    Segelov, Eva
    Thavaneswaran, Subotheni
    Waring, Paul M.
    Desai, Jayesh
    Robledo, Kristy P.
    Gebski, Val J.
    Elez, Elena
    Nott, Louise M.
    Karapetis, Christos S.
    Lunke, Sebastian
    Chantrill, Lorraine A.
    Pavlakis, Nick
    Khasraw, Mustafa
    Underhill, Craig
    Ciardiello, Fortunato
    Jefford, Michael
    Wasan, Harpreet
    Haydon, Andrew
    Price, Timothy J.
    van Hazel, Guy
    Wilson, Kate
    Simes, John
    Shapiro, Jeremy D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (19) : 2258 - +
  • [40] COST-EFFECTIVENESS OF CETUXIMAB AND BEVACIZUMAB IN THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) FOR PATIENTS WITH KRAS WILD-TYPE TUMOURS IN THE UNITED KINGDOM
    Samyshkin, Y.
    Hertel, N.
    Griebsch, I
    VALUE IN HEALTH, 2011, 14 (07) : A446 - A447
12345